Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 11th International Conference on Genomics and Pharmacogenomics Philadelphia, Pennsylvania, USA.

Day 2 :

Keynote Forum

Dr.Genhua Pan

Professor and Head of Wolfson Nanomaterials & Devices Laboratory at University of Plymouth, UK

Keynote: Title : Graphene biosensors for label free detection of blood based biomarkers for Alzheimer’s disease
Genome 2018 International Conference Keynote Speaker Dr.Genhua Pan photo

Genhua Pan is a Professor and Head of Wolfson Nanomaterials & Devices Laboratory at University of Plymouth, UK and Coordinator of EU H2020 Marie Curie network BBDiag. He has over 30 years of research and teaching experience in micro/nano scale thin films and devices, information storage technology and electronic engineering. His current research interest encompasses graphene & 2D materials/devices, biosensors, renewable energy/solar cells, spintronics and magnetic data storage. Genhua graduated from Zhejiang University, China in 1981, worked in the Chinese Academy of Science until 1988 when he obtained a scholarship to visit Loughborough University for a year. He then joined Plymouth University in 1989, gained my PhD in materials and physics in 1993. Over the years, He has also worked with a number of institutions as a visiting researcher (Sony Research Centre, Yokohama, Japan, Akita Institute of Technology, Akita, Japan, and Seagate Technology, Northern Island). To date he has published over 100 journal and conference papers, 3 book chapters and 6 patents.



Statement of the Problem: Alzheimer’s disease is the most common form of dementia leading to a massive irreversible neuronal loss and cognitive decline. It affects over 7 million people in Europe and 5.5 million in America and this figure is expected to double every 20 years as the population ages. Early detection of AD is the key requirement for developing disease modifying treatments as studies show that pathology exceeds symptom by years. The existing techniques for detection using CSF and Imaging biomarkers are highly expensive and invasive. Blood based biomarkers, however, can provide a simple and effective way for the screening of AD patients. The talk covers the latest progress in the EU H2020 BBDiag research project, for the development of blood biomarker based diagnostics for early stage AD employing by multiplxed graphene biosensor arrays. Methodology & Theoretical Orientation: Two novel graphene biosensors were developed for label-free detection of DNA and protein biomarkers, a graphene immunoFET for detection of protein markers and an rGO-graphene electrode for detection of DNA markers. Findings: The rGO electrode shows enhanced redox current up to 40% higher in comparison with electrodes of bare graphene due to the combination of high number of electroactive sites on rGO and high conductivity of pristine graphene. A linear range from 10-7M to 10-12M is demonstrated for the biosensor with a detection limit of 1.58 x 10-13M. The immunoFET showed a unique resistance change pattern with high reproducibility and an ultralow detection limit of 1pg mL-1 and high sensitivity of 0.30 Ω/ng/mL. Conclusion & Significance: We have demonstrated that graphene biosensors can be employed for ultra-sensitive and label-free detection of DNA and proteomic disease biomarkers. The work may lead to the development of cost effective and minimally invasive point of care diagnostic devices for routine screening of Alzheimer’s disease with a panel of biomarkers

Keynote Forum

Ron L Martin

Founder and President, Nutrigenetics Unlimited, Inc., USA

Keynote: Genetics/genomics for both treatment and prevention: The evidence-base.
Genome 2018 International Conference Keynote Speaker Ron L Martin photo

Ron Martin received his BS and MS degrees in Food Science and Nutrition from Chapman University, in Orange, California.  He worked for more than 35 years in the nutraceutical and food industries, including Hunt-Wesson/ConAgra, Plus Products, the William. T. Thompson Co., and the Nutrilite division of Alticor, where he served as Senior Research Scientist in Nutrilite's New Concepts group.  Ron has been a Professional member of the Institute of Food Technologists (IFT) and is President of Nutrigenetics Unlimited, Inc., which he founded in 2007 ( He is also one of the founding members of the International Society of Nutrigenetics/Nutrigenomics (ISNN,



The emerging genetics/genomics evidence-base for both treatments and prevention will be described, along with online tools for increasing both awareness and utility of the increasingly actionable information. This can be helpful to the entire spectrum of potential users, including students and other members of the public. Such tools are increasingly important as the body of literature continues to expand rapidly, making it progressively more difficult to identify and manage the evidence-base for making genetics-informed choices. Online resources will be described, including the usefulness of standardized terminology which allows creation of subtopic listings for any given topic, or for any given combination of topics – including for genes and gene variants. Beyond diagnosis and treatment alone, such approaches also allow identification and exploration of prevention opportunities (both embracement and avoidance). Such information can be useful for pursuing both physical and mental health. Gene-environment examples include nutrition, pharmaceuticals, pollution, lifestyle, social environment, etc. Because nutrition applies to everyone without exception, it can become a useful introductory "archetype" for promoting greater engagement, and greater genetics/health literacy.


Keynote Forum

Dr. David I Smith

Department of Laboratory Medicine and Pathology,Mayo Clinic,USA

Keynote: Whole Genome Sequencing Strategies to Characterize Human Papillomaviruses Role in the Development of Cancer
Genome 2018 International Conference Keynote Speaker Dr. David I Smith photo

David I Smith is the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. He is an expert of advanced DNA sequencing methodologies and how to use these to study the molecular alterations that occur during cancer development. His research focuses on the different roles that human papillomavirus plays in the development of different cancers. His group also studies genome instability during cancer development and the role that the common fragile sites plays in this.


Human papillomavirus (HPV) is involved in the development of a number of anogenital cancers and is increasingly involved in the development of oropharyngeal squamous cell carcinoma (OPSCC), a cancer of the base of the tongue and the thyroid. Much of what is currently known about HPVs role in cancer development comes from studies of cervical cancer. Women whole immune system does not clear the HPV virus are at an increased risk of developing cervical cancer. Infection of the cervical epithelium with HPV causes cellular immortalization but additional alterations are required for invasive cancer to develop. One such alteration in integration of the HPV virus into the human genome which is observed in most, but not all, cervical cancers. We have been studying HPVs role in the development of OPSCC using several whole genome sequencing strategies. The first is mate pair next generation sequencing on the Illumina sequencing platform. The second is whole genome sequencing (WGS) on the BGI sequencing platform. These studies have revealed that HPVs role in the development of OPSCC is different that in cervical cancer as HPV is only integrated in about 30% of HPV-positive OPSCCs. Furthermore these studies have demonstrated that HPV plays different roles in the development of different OPSCCs. WGS not only can determine where HPV has integrated into the human genome but also the structure of the chromosomal region after the integration event. WGS can also characterize many other genomic alterations that occur in these cancer genomes. I will describe our work characterizing how we’ve utilized genome sequencing to study HPVs role in the development of OPSCC.


Keynote Forum

Krishna Dronamraju

Foundation for Genetic Research, President of the Foundation for Genetic Research,USA

Keynote: Genomics and ELSI (ethical, legal, and social issues)
Genome 2018 International Conference Keynote Speaker Krishna Dronamraju photo

Dr. Krishna Dronamraju is President of the Foundation for Genetic Research in Houston and a Visiting Professor of the University of Paris. He is the author of 20 books in Genetics, Biotechnology and History of Science. He had been an Advisor to the U.S. Government in Genetics and Biotechnology in relation to Health and Agriculture. His research interests include the ethical and social impact of genetic applications, human gene therapy, and history of genetics. 


J.B.S. Haldane (1923) was the first to emphasize the ethical impact of Genomics. Gene-based diagnostics and therapeutics are being widely integrated into healthcare today. However, there are barriers to accessing these new technologies for the public worldwide. An important role for all nurses will be to make sure that the health and social needs of the public are being met, including addressing the technological inequities in accessing genomic health care worldwide. This requires a major shift in emphasis to a more global view of health and disease.

The basis for equal access to genomic health care around the world can be found in the World Health Organization’s Proposed Guidelines on Ethical Issues in Medical Genetics and Genetics Services. The core public health function of assurance includes making sure that the general public has access to and quality of genomic healthcare, and informing populations about relevant genomic health issues and services. The World Health Organization document emphasizes the importance of education about genetics for the public and all healthcare professionals noting the profound economic and technological inequities that exist between nations.

Governmental agencies can assist in promoting genetic and genomic healthcare around the world. In the United States, the Centers for Disease Control and Prevention (CDC) has taken a leading role in addressing issues of access to genetic and genomic resources by creating multiple tools and resources that address the role of genetics in public health. Health care workers can take a leading role working with state, federal, and international health agencies to provide guidance to health systems with regard to decisions about utilization of genetics and genomics services. The opportunities to fully participate in genomic healthcare throughout the healthcare continuum, for all populations, and at all stages in the lifespan are multiple. The challenge is to ensure that the workforce is prepared and competent to provide genetic and genomic care. Knowledge and understanding of current and emerging ethical issues is an essential component of this knowledge base. 



Keynote Forum

John Powers

Co-Founder at Murrieta Genomics,USA

Keynote: Genomics the Cellular Evolution of Medicine
Genome 2018 International Conference Keynote Speaker John Powers photo

John Powers has spent his entire professional career in high tech, first in the wireless industry and for the past 10 years, John has worked in the medical industry specifically focused on halting cancer. As CEO of IntraOp Medical, John worked with multidisciplinary teams including physicists, surgeons, radiation and medical oncologists in the top cancer centers around the world. Working with the Centers for Medicare & Medicaid Services (CMS) John was able to secure a new reimbursement code and reimbursement for Intra-Operative Radiation Therapy (IORT).  John’s work with IntraOp led him to an interest in gene-based technologies available to foil cancer, before a tumor can grow or metastasize. John has spent the past 3 years working with cancer and surgical centers promoting and expanding genetic and genomic testing. He is committed to the expansion and incorporation of gene sequencing in conventional medicine.


Statement of the problem: The current trajectory of healthcare costs is unsustainable without major changes. The lack of uniformity, true competition and focus on reimbursement as opposed to cost has greatly contributed to the out of control cost in current health systems. In addition, the number of doctors and medical professionals cannot keep pace with the growing demand. There are a number of other areas contributing as well, and the trajectory has to change. Healthcare “digitization” has been happening at all levels of the healthcare continuum and will provide the tools and understanding to move the medical industry to the health industry and allow the patient to take a more active part in determining their correct path.

Enabling technology: Next Generation Technology (NGS) is an incredible enabling technology. It has the potential to impact medical the same was Code Division Multiple Access (CDMA) impacted the cellular market. Leading to unlimited calling plans and an explosion of data applications. NGS will help drive new cost milestones due to the volume and quality of information that can be derived from a single NGS test. DNA, RNA, Microbiome, epigenetics, and other omics. NGS driven testing is already having positive impacts in diagnosis, pain management, nutrition, imaging, treatment planning, radiation therapy, chemotherapy, surgery, and surveillance. This is not a comprehensive list, but provides an idea of the vast amount of data NGS can produce.

Conclusion: Just like in the cellular communications market, the applications, software and applications will evolve over the next decade to fully utilize the power of NGS. The medical market is looking to neural networks, deep learning and artificial evolution programming. These two industries are going to continue to converge as part of medical evolution.